Kornimate/medical-research-clean huggingface dataset:
emotion tracking study for residents

Conditions: Stress, Emotional

Summary: the proposed study will develop and pilot a fourteen-day assessment tailored for the high-demand schedule of residents through a smart phone intervention, emotrak.emotrak uses ecological measurement assessment (ema), which solicits real-time user feedback at various time points across a series of days or weeks.

the investigators will perform a randomized controlled trial that compares residents, using emotrak with a wait list control group. after two weeks, the active control group becomes the treatment group. all participants will be evaluated four times from at baseline to two months. the measures to explore for any pre and post change are stress reduction on the emotional exhaustion scale of the maslach burnout inventory (mbi) and improved resilience on the perceived stress scale (pss).

Eligibility criteria:
inclusion criteria: * currently in residency or fellowship at ucsf exclusion criteria: * not having an iphone
intravenous fat emulsion comprised of fish oil in the treatment of parenteral nutrition induced liver injury in infants

Conditions: Total Parenteral Nutrition-induced Cholestasis

Summary: to provide a mechanism for critically ill infants with parenteral nutrition (pn) associated cholestasis to receive omegaven for compassionate use situations for which there are no satisfactory alternative treatments.

compassionate use

Eligibility criteria:
inclusion criteria: 1. critically ill infants with either a known anatomic short gut (greater than 50% of the bowel removed) or known severe dysmotility of the gut reflecting non-functional gut similar to anatomic short gut will be offered omegaven® when their direct bilirubin reaches 2 mg/dl. infants who do not meet the above criteria for anatomic or dysfunctional short gut will be allowed to receive omegaven® when their direct bilirubin reaches 4 mg/dl. the qualifying measurements of 2 mg/dl or 4 mg/dl direct bilirubin must be consecutive and obtained at least 24 hours apart. 2. be expected to require intravenous nutrition for at least an additional 28 days 3. patient must have documented failure of or ineligibility for the following therapies to prevent progression of pnald: * reduction of intralipid® to 1 g/kg/day * limiting trace minerals including copper and manganese * initiation and use of ursodiol * cycling of parenteral nutrition * advancement of enteral feedings 4. parental informed consent must be signed. exclusion criteria: 1. have a congenitally lethal condition (e.g. trisomy 13). 2. have clinically severe bleeding not able to be managed with routine measures. 3. have evidence of a viral hepatitis or primary liver disease as the primary etiology of their cholestasis. 4. have other health problems such that survival is extremely unlikely even if the infant's cholestasis improves. 5. has culture positive sepsis

Keywords: omegaven cholestasis parenteral nutrition associated liver disease
study of a new contact lens cleaning and disinfecting solution

Conditions: Vision Disorders

Summary: the objective of this study is to evaluate the safety and efficacy of a new investigational cleaning and disinfecting solution (test) compared to clear care cleaning and disinfecting solution (control) when used by contact lens wearers to clean and disinfect their contact lenses for approximately three months.


Eligibility criteria:
inclusion criteria: * subjects must be habitual wearers of one of the protocol specified lenses. * subjects must habitually use a non-peroxide lens care product for cleaning, disinfecting and storage of their lenses. * subjects must be adapted lens wearers and wear a lens in each eye and each lens must be of the same manufacture and brand. * subjects must agree to wear their lenses on a daily wear basis for approximately three months. exclusion criteria: * subjects who currently use a hydrogen peroxide cleaning and disinfecting solution. * subjects who currently wear opaque cosmetic tint contact lenses. * subjects who have worn polymethylmethacrylate (pmma) lenses within the last three months. * subjects with any systemic disease currently affecting ocular health or which in the investigator"s opinion may have an effect on ocular health during the course of the study. * subjects using any systemic or topical medications that will, in the investigator"s opinion, affect ocular physiology or lens performance. * subjects with any "present" finding during the slit lamp examination that, in the investigator"s judgment, interferes with contact lens wear. * subjects with any scar or neovascularization within the central 4 mm of the cornea. * subjects who are allergic to any component in the study care products.

Keywords: contact lens cleaning solution
skills for talking about cannabis for families of young adults with psychosis

Conditions: Caregiver Burden; Cannabis Use; Expressed Emotion; Communications Skills

Summary: the objectives of this research is to (1) create a family intervention and provider manual to train family members of young people with psychosis (yp-p) who are heavy cannabis users new communication skills to motivate change in the yp-p's cannabis use, (2) pre-test the intervention with 10 family member participants and adapt the intervention based on their recommendations, and (3) evaluate the feasibility and acceptability of the intervention in a randomized pilot trial (n=40). the investigators anticipate that the intervention will improve family participants' communication skills, decrease expressed emotion and caregiver burden. the investigators anticipate that improvements in communication skills, expressed emotion and caregiver burden will lead to decreases in the cannabis use of their yp-p.

the objectives of this research will be implemented in two phases. phase ii will develop a family intervention informed by a stakeholder advisory board and pre-test the intervention will be adapted with 10 family member participants. the intervention based on recommendations in phase 1. the investigators anticipate that the intervention will improve family participants' communication skills, decrease expressed emotion and caregiver burden. the investigators anticipate that improvements in communication skills, expressed emotion and caregiver burden will lead to decreases in the cannabis use of their yp-p. phase 2 will evaluate the acceptability, feasibility, and preliminary effect sizes of the intervention in a pilot randomized controlled trial comparing it to treatment as usual (tau) with 40 family participants. this pilot test is consistent with the stated purpose of stage 1b of the nih stage model for behavioral intervention development and the r34 mechanism of "providing resources for evaluating the feasibility, tolerability, acceptability and safety and preliminary effectiveness of approaches to improve mental health/functional outcomes". the purpose of this pilot study is to develop and test the feasibility and acceptability of the intervention protocol, study procedures, and recruitment plan. secondarily, the investigators intend to collect data to inform effect size estimates on outcomes to plan for an r01.

Eligibility criteria:
inclusion criteria: 1. aged 18 years or older, 2. has a loved one who is both in csc treatment for fep and has used cannabis on at least 9 days in the past 30, 3. has at least 10 hours of contact per week with their loved one with fep. it is assumed that ya-p will be aged 13-40 with schizophrenia spectrum disorder given criteria for csc enrollment. exclusion criteria: 1. unable to read study materials and communicate feedback in english 2. do not have access to zoom

Keywords: coordinated specialty care cannabis use disorder first episode psychosis caregiver burden cannabis use communication skills
oral administration of alequeltm for patients with inflammatory bowel disease (ibd)

Conditions: Crohn's Disease

Summary: oral administration of alequel, a mixture of proteins derived from the patient's bowel will be tested in patients with inflammatory bowel disease.

oral administration of alequel prepared from patients biopsies will be tested in patients with inflammatory bowel disease to determine its anti inflammatory effect.

Eligibility criteria:
inclusion criteria: * crohn's disease exclusion criteria: * immune suppression
the assess national multi-center prospective cohort

Conditions: Primary Sjögren's Syndrome

Summary: the assess national multi-center prospective cohort (assessment of systemic complications (signs) and evolution in sjögren's syndrome "ss") was set up in 2006 thanks to a grant of the french ministry of health. fifteen centers for autoimmune diseases consecutively included consecutive patients with primary sjögren's syndrome "pss" fulfilling american-european consensus criteria (aecg) between 2006 and 2009. the study was approved by the ethics committee of bichat hospital in 2006. all patients gave their informed written consent. this study was followed for 5 years with the grant of the french ministry of health and this study will be extended for 20 years by french society of rheumatology (sfr). on an annual basis for a duration of 20 years, a thorough standardized paper case report form (crf) was filled prospectively by clinicians.

primary sjögren's syndrome (pss) affects 0,1% of the population. this systemic autoimmune disease is characterized by disabling dryness, fatigue and pain, and systemic complications in 30% of patients. no treatment has proven effective in this disease. the previous or present systemic complications included skin, articular, lung, kidney, peripheral and central nervous system, muscular involvement and vasculitis, as well as lymphoma occurrence were recorded. for previous lymphoma, the diagnosis and the histological subtypes were confirmed by reanalysis of the medical and histological records. the objective of this cohort was to assess systemic complications (signs) and evolution of patients with pss and to determine the evolution and factors predictors of lymphoma of systemic complications and lymphoma in pss during a 20-years prospective follow-up. this cohort was successful in rheumatology field, 395 patients was recruited for 2 years in 15 french centers (10 rheumatology and internal medicine 5) and followed for 5 years until july 2014. the primary objective of this cohort is to assess the evolution of primitive sjogren syndrome patients and to determine predictors factors of lymphoma and systemic complications during a 20-years prospective follow-up.

Eligibility criteria:
inclusion criteria: * aged of 18 years or more * primary sjögren's syndrome patients who have already participated to the study assess exclusion criteria: * secondary sjögren's syndrome (sj) associated with other autoimmune diseases

Keywords: primary sjögren's syndrome (pss) auto-immune diseases
effects of sustained natural apophyseal glides combined with kinesiotaping in patients with chronic mechanical neck pain: a randomised controlled trial

Conditions: Neck Pain

Summary: this study is a randomized controlled trial and its purpose is to determine the combined effects of sustained natural apophyseal glides and kinesiotaping on pain, range of motion and neck disability in patients with chronic mechanical neck pain.

this study aims to determine the combined effects of sustained natural apophyseal glides and kinesiotaping in chronic mechanical neck pain patients of age range 18-40. outcome variables are pain, range of motion and functional disability of neck which will be determined by using the following respective data collection tools: 1. numeric pain rating scale 2. inclinometer 3. neck disability index participants of interest will be approached and explained about the research. they will be randomly allocated in to two groups. informed written consent will be taken. the intervention protocol will be comprised of six sessions over a 2-week period (3 sessions per week on alternate days). outcome measures will be assessed at baseline and after 2 weeks. data will be analyzed and interpreted using spss.

Eligibility criteria:
inclusion criteria: * mechanical neck pain * age range: 18-40 years * both males and females * having pain from at least last 3 months (chronic) * pain score greater than 3 on nprs * pain and limitation on neck moverment exclusion criteria : * recent surgery of spine, temporomandibular joint or shoulder in the previous 12 months. * open wound around neck. * history of traumatic injuries or fractures in the cervical spine. * history of neurological and cardiac pathologies. * history of some serious pathologies (e.g., malignancy, inflammatory disorder etc.). * history of cervical or shoulder neurological movement disorder. * cervical spondylolisthesis, cervical radiculopathy, and spinal stenosis. * vascular syndromes such as basilar insufficiency. * diagnosed psychiatric disorders such as anxiety and depression. * interventions including medications, exercise or physical therapy in the last 3 months. * any other condition that contraindicates kinesiotaping such as skin sensitivity.
the relationship of defeverscence and itraconazole plasma level study in immunocompromised participants

Conditions: Hematologic Neoplasms; Neutropenia; Fever

Summary: the purpose of this observational study is to investigate whether a sufficient concentration of itraconazole can influence disappearance of a fever (defeverscence) when intravenous (into the vein) itraconazole is administered for resolving unknown neutropenic fever of participants who are given itraconazole oral solution as a prophylaxis under general treatment conditions.

this is a prospective (study following patients forward in time), open-label (all people know the identity of the intervention), multi-center (conducted in more than one center) observational study to examine the correlation between a sufficient blood concentration of itraconazole and disappearance of a fever (defeverscence) when itraconazole injection is administered for resolving unknown neutropenic fever of participants who are given itraconazole oral solution as a prophylaxis under general treatment conditions. the recommended dose of the drug will be 200 milligram (mg), which will be administered intravenously, twice daily for 2 days (a total of 4 doses) and then 200 mg once daily for 12 days. after the administration for a total of 14 days, itraconazole oral solution 200 mg (which is equivalent to 20 ml) twice daily will be continued for a total of 14 days until clinically significant neutropenia is resolved.

Eligibility criteria:
inclusion criteria: * immunocompromised participants with neutropenic fever who have been treated with itraconazole oral solution as prophylaxis * female participants who are postmenopausal or received contraceptive operation or refrain from sexual relations and women of childbearing potential should conduct an effective method of birth control (oral contraceptives, injections, intrauterine device, double barrier method, contraceptive patch and male partner's sterilization) before participation and during the study * male participants who will not have a baby within 2 months after the completion of itraconazole therapy exclusion criteria: * fever due to documented deep-seated fungal infection at the entry into the study, but documented candidemia will be included * participants with kidney function related abnormalities with calculated creatinine clearance of 30 milliliter per minute (ml/min) or lower * aminotransferase level 5 times or higher of normal limit and total bilirubin level 5 milliliter per deciliter (ml/dl) or higher due to hepatic dysfunction * participants with dementia (mental decline) related to head injury and hypoxic brain injury * participants with mental illness which may interfere with cooperation in treatment and monitoring condition of the clinical study

Keywords: hematological neoplasms neutropenia fever itraconazole sporanox antifungal prophylaxis defeverscence
screening for social weaknesses and coordination course of cancer patients

Conditions: Cancer

Summary: the main objective of the study is to validate a methodology with psychometric tool to measure levels of patients social fragility. this tool will be dematerialized on a tablet. the answers will be then processed by a decision support algorithm, which automatically send an alert to detection of social fragility of the patient to the nurse navigators.


Eligibility criteria:
inclusion criteria: * all new patients enter icln for a diagnosis of cancer * patients who can read french or patients who can not read french, but accepting the translation by a close friend or family * patient having signed a free and informed consent exclusion criteria: * refusal of participation, major patients protected under guardianship. * patient can not read french without possibility of translation by a close friend or family
role of oxidative stress in ovarian tissue after co2-pneumoperitoneum application-induced i/r

Conditions: Oophorectomy; Oxidative Stress; Ischemia Reperfusion Injury

Summary: because of cellular changes in response to ischemia and a following period of reperfusion, damages to organs and different tissues occur. there are several ongoing studies to enlighten the pathophysiological processes underlying these damages inflicted by ischemia/reperfusion. gases (co2) with low water content are used in pneumoperitoneum, which is a procedure to inflate the abdominal cavity with an appropriate gas for laparoscopic operations. in the current literature, it was shown that due to a restricted blood flow during the gas insufflation, ischemia develops and with the reperfusion of the organ in deflation period, oxidative stress and inflammation increases, leading to ischemia/reperfusion-related organ and tissue damages. in the proposed study, biomarkers for ischemia/reperfusion-inflicted damage will be evaluated in a biochemical and histopathological perspective in biopsy samples of ovaries from a young patient group in which hysterectomy and bilateral salpingo-oophorectomy will be performed, laparoscopically.

in the laparoscopic salpingo-oophorectomy, after the induction of anesthesia, an umbilical skin incision was performed. pneumoperitoneum was established using dry, nonheated co2 insufflation through a veress needle. a 10-mm trocar was inserted into the abdominal cavity through the umbilical incision for the laparoscope. subsequently, three 5-mm ancillary trocars, 2 on the lower abdominal quadrants and 1 on the left upper quadrant, were introduced to the abdominal space under direct optic visualization. iap was set at 14 mm hg and maintained with a gas insufflator (endoflator; karl storz endoscopy, tuttlingen, germany)immediately after the port placement, unilateral oophorectomy was performed, and ovarian biopsies were obtained. the operation continued with ligation and transection of the contralateral utero-ovarian ligament and the bilateral round ligaments. the contralateral infundibulopelvic ligament, which contains the main vascular supply for the contralateral ovary, remained intact. subsequently, anterior and posterior leaflets of the broad ligament were identified and dissected, and the bladder was placed away from the lower uterine segment. the uterus removed from vaginal way after necessary steps. after desufflation, the cuff closure procedure was performed vaginally. at the end of the closure, pneumoperitoneum was reestablished, the remaining contralateral ovary was removed immediately, and biopsies were obtained for histologic analyses.

Eligibility criteria:
inclusion criteria: * transgender men who wants to remove their uterus and both ovaries. exclusion criteria: * known endometriosis * hysterectomized patient * unacceptance to involve to the trial * suspicion of malignancy
protective effects of normobaric hyperoxia on blood brain barrier in patients with acute ischemic stroke

Conditions: Stroke, Acute

Summary: the purpose of this study is to find out a serum marker for the evaluation of blood brain barrier damage based on animal experiments and investigate the effect of nbo（normobaric hyperoxia）on blood brain barrier in the acute ischemic stroke patients who received r-tpa thrombolytic therapy.


Eligibility criteria:
inclusion criteria: 1. male or female with age from 18 to 85; 2. acute ischemic stroke; 3. national institutes of health stroke scale (nihss) score of 4-25 4. mrs score less than 1 before onset of stroke symptom; 5. onset of stroke symptoms within 4.5h before initiation of intravenous r-tpa thrombolytic therapy; 6. informed consent obtained exclusion criteria: 1. stroke or serious head trauma within the previous 3 months 2. major surgery or severe trauma with in the preceding 3 months 3. intracranial hemorrhage 4. systolic pressure greater than 185 mm hg or diastolic pressure greater than 110 mm hg, or aggressive treatment intravenous medication) necessary to reduce blood pressure to these limits 5. symptoms rapidly improving 6. symptoms suggestive of subarachnoid hemorrhage, even if ct scan was normal 7. gastrointestinal hemorrhage or urinary tract hemorrhage within the previous 21 days 8. arterial puncture at a noncompressible site within the previous 7 days 9. seizure at the onset of stroke 10. platelet count of less than 100,000 per cubic millimeter 11. received heparin within the 48 hours preceding the onset of stroke and had an elevated partial-thromboplastin time 12. received oral anticoagulation therapy preceding the onset of stroke and inr greater than 1.7 or prothrombin times greater than 15 seconds 13. ct showed a multiple infarction (low density area greater than 1/3 cerebral hemisphere) 14. severe hepatic or renal dysfunction 15. active and chronic obstructive pulmonary disease or acute respiratory distress syndrome; 16. \>3 l/min oxygen required to maintain peripheral arterial oxygen saturation (sao2)﹥95% as per current stroke management guidelines; 17 medically unstable; 18. inability to obtain informed consent. 19. life expectancy\<1 years 20. pregnant or breast-feeding women 21. unwilling to be followed up or poor compliance for treatment 22. patients being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial

Keywords: normobaric hyperoxia r-tpa thrombolytic therapy
indicators of inflammation and coagulation in sepsis

Conditions: Sepsis

Summary: we will collect blood samples from patients with the diagnosis of sepsis and other icu patients. we will describe the course of different mediator levels and organ injury markers and follow their progression throughout the course of the study.

after informed consent is obtained 5 cc of blood is collected on the day of admission and on days 0, 1, 3, and 7 thereafter. plasma is collected and frozen for the subsequent measurement of biomarkers.

Eligibility criteria:
inclusion criteria: * admission to the icu exclusion criteria: * no blood draws scheduled * hemoglobin level \< 6,5 gm/dl

Keywords: sepsis organ failure cytokines clotting factors
the effect of music on pain, anxiety and satisfaction during intrauterine device application

Conditions: Reproductive Health; Pain; Women Health

Summary: this study was planned to determine the effect of music listened to during intrauterine device application on pain,anxiety and satisfaction.

the randomized controlled and experimental study will be conducted with 70 women who apply to a maternal and child health and family planning center to have an intrauterine device (iud). women in the experimental group (n=35) will listen to music before, during and after the iud application process, and the control group (n=35) will undergo routine iud application. information form containing sociodemographic information, situational anxiety

Eligibility criteria:
inclusion criteria: * knowing how to read and write, * not having had an iud inserted before, * being between the ages of 18-49, * no hearing-related problems, * not having used analgesic or anesthetic medication within 24 hours before or during the procedure, * voluntarily participating in the study, exclusion criteria: * the woman has a cognitive and auditory problem * having a history of cervical surgery

Keywords: intrauterine device pain anxiety satisfaction